- Brief Overview of SCLC
- Immuno-Oncology in Untreated ES-SCLC
- Treatment Approaches in Previously Treated ES-SCLC
- Key Clinical Trials in LS- and ES-SCLC
- Closing Remarks and Question-and-Answer Session
Date / Time
Christine L. Hann, MD, PhD
Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Mark A. Socinski, MD
Executive Medical Director
Member, Thoracic Oncology Program
Florida Hospital Cancer Institute
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging therapies for treatment of SCLC.
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with small-cell lung cancer.
Upon completion of this activity, participants should be able to:
- Integrate into practice the results of clinical trials demonstrating improved outcomes for patients with ES-SCLC using immune checkpoint inhibitor–based combinations
- Delineate the dose, schedule of administration, and dose adjustments for each of the immune checkpoint inhibitor and etoposide/platinum combinations currently indicated for ES-SCLC
- Plan therapeutic strategies for patients with metastatic SCLC and disease progression on or after platinum-based chemotherapy
- Manage immune-related adverse events using available clinical data, guidelines, and online clinical resources and tools
- Identify patients with SCLC who are appropriate for enrollment on ongoing clinical trials
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-058-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.